Dr Shannon E Boye, Co-Founder and Chief Scientific Officer of Atsena Therapeutics, writes about the company’s journey to the clinic for a challenging ocular gene therapy target. I have… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research in women’s health uncovered significant findings related to endometriosis and… Read More
Biotechnology company Beacon Therapeutics has raised over $75 million to advance treatments for ocular diseases. The funding was raised in an oversubscribed Series C financing round, led by Life Sciences at Goldman Sachs Alternatives and with participation from the Retinal Degeneration Fund (RD Fund), the venture arm of… Read More
News round-up for 12 – 16 January by Bruno Quinney, Content Team at DDW. This week in DDW, new research in women’s health has uncovered significant findings related to endometriosis and ovarian cancer. Elsewhere, can ageing be reversed? The top stories: Discovery reveals endometriosis is not… Read More
Scientists have uncovered new genetic causes of sight loss, paving the way for a genetic diagnosis for thousands of people. Researchers, analysing data from Genomics England’s National Genomic Research Library (NGRL), found five new genetic causes of retinitis pigmentosa (RP), an eye condition that causes gradual blindness. Read More
A new spinout has launched from the University of Birmingham targeting treatments for the leading causes of preventable blindness. Healome Therapeutics is developing a platform that delivers a ‘pro-healing’ microenvironment for causes of preventable blindness. The company’s platform will be targeted at ocular surface diseases, which are… Read More
